
Sign up to save your podcasts
Or


Recorded on 11/10/23
TD Cowen analyst Yaron Werber speaks with Chris Garabedian, co-founder, chairman, and CEO of Xontogeny and Portfolio Manager of the Perceptive Advisors Ventures Fund. Chris shares his insights about 1) what makes or breaks a successful biotech from his time at Gilead, Celgene, and Sarepta, 2) how investing has changed now that interest rates are high and capital is expensive, and 3) his investment philosophy at Xontogeny and advice to other early-stage investors.
For Disclosures, click here bit.ly/3cPHkNW
https://go.td.com/PodcastDisclosure
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By TD Securities, TD Cowen4.8
3636 ratings
Recorded on 11/10/23
TD Cowen analyst Yaron Werber speaks with Chris Garabedian, co-founder, chairman, and CEO of Xontogeny and Portfolio Manager of the Perceptive Advisors Ventures Fund. Chris shares his insights about 1) what makes or breaks a successful biotech from his time at Gilead, Celgene, and Sarepta, 2) how investing has changed now that interest rates are high and capital is expensive, and 3) his investment philosophy at Xontogeny and advice to other early-stage investors.
For Disclosures, click here bit.ly/3cPHkNW
https://go.td.com/PodcastDisclosure
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

3,064 Listeners

4,673 Listeners

1,942 Listeners

9,514 Listeners

947 Listeners

123 Listeners

321 Listeners

1,048 Listeners

286 Listeners

1,299 Listeners

10,026 Listeners

34 Listeners

522 Listeners

1,427 Listeners

37 Listeners